ProImmune

What ProImmune does

ProImmune Ltd is a privately held UK life-sciences company headquartered in Oxford that develops and commercializes immunological reagents and contract research services used to study and manage adaptive immune responses. Its core reagent platform is built on Major Histocompatibility Complex (MHC) technology, including Pro5 MHC Class I Pentamers, ProT2 MHC Class II Tetramers, ProM1/ProM2 monomers, and CD1d/MR1 tetramers that enable detection of antigen-specific T cells in flow cytometry. The company has built a differentiated second platform, Ankyrons — engineered ankyrin-repeat scaffold proteins (~15 kDa) selected in vitro from trillion-clone ribosome-display libraries without animal immunization — that are positioned as reproducible, affinity-mature alternatives to conventional antibodies across 60+ pathogen and disease targets.

ProImmune monetizes through three revenue streams: catalog and custom reagent sales (pentamers, tetramers, monomers, Ankyrons, peptides via its thinkpeptides brand) distributed through a direct sales force, e-commerce storefront, and distributor network; fee-for-service contract research assays including ProPresent antigen presentation, ProMap/ProScern proliferation assays, REVEAL/ProVE MHC-peptide binding for epitope discovery, ProStorm cytokine release, ProSpot ELISpot, immunogenicity risk assessment, and HLA typing; and custom synthesis/development work (custom Ankyrons, custom multimers, peptide libraries). Pricing is quote-based and not publicly disclosed.

The customer base spans large pharmaceutical companies (Pfizer, Novartis, GSK, Roche, Bristol-Myers Squibb, Bayer, Dr. Reddy's), biotechnology firms (Adaptimmune, Immunovaccine), academic medical centers (University of Oxford, Harvard Medical School, Duke-NUS, Karolinska, Fred Hutchinson), and government agencies (USAMRIID, FDA, DSTL). Applications span vaccine and biotherapeutic immunogenicity, infectious disease (including BSL-4 pathogens), cancer immunotherapy, autoimmunity, transplantation, and emerging veterinary/animal health work. The company sells globally through regional sales contacts in the US/Canada, Asia-Pacific, and the UK/EU, with named distributor relationships in international markets.

Name

ProImmune

Legal name

ProImmune Ltd

Website

https://proimmune.com

Company type

Private

Founded year

2001

Operating status

Operating

Headcount range

11–50 employees

Short description

ProImmune is a UK-based life sciences company that develops MHC-based immunological reagents (pentamers, tetramers, monomers) and proprietary Ankyron binding proteins, alongside contract research services for immunogenicity and T cell epitope analysis, serving pharma, biotech, academic, and government customers worldwide.

Ownership category

akta.pro rank

Product category

Immunology Reagents and Contract Research Services

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAGAIAI

Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)

Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Laboratory Equipment, Instruments & Consumables

SECONDARYHLAAAMAL

Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)

Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

SECONDARYHLAAAIAA

High-Throughput Screening & Assay Platforms (HTS/HCS, phenotypic screening)

Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

• Immunological reagents
• MHC multimers
• Custom peptide synthesis
• Immunogenicity assays
• T cell research

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Immunological Reagent Products: Sale of proprietary immunological reagents including Ankyrons, MHC Pentamers, Tetramers, Monomers, CD1d/MR1 Tetramers, and peptide products. Products sold through catalog, custom synthesis, and e-commerce platform.
2. Contract Research Services: Fee-for-service laboratory assays including immunogenicity testing, T cell proliferation assays, cytokine release assays, ELISpot assays, HLA typing, and custom assay development. Services support preclinical and clinical drug development.
3. Custom Synthesis & Development: Custom peptide synthesis, custom Ankyron development, and custom multimer production based on specific customer research requirements.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

ProImmune develops, manufactures, and sells proprietary immunological reagents — including Ankyron® target binding proteins, MHC Class I Pentamers (Pro5®), MHC Class II Tetramers (ProT2®), MHC monomers (ProM1/ProM2, ProVE® SL), CD1d and MR1 Tetramers, and custom peptides (thinkpeptides®) — for immunology research. The company also provides fee-for-service contract research assays such as ProPresent® antigen presentation assays, ProMap®/ProScern® T cell proliferation assays, REVEAL®/ProVE® MHC-peptide binding assays, ProStorm® cytokine release assays, ProSpot® ELISpot assays, and typeHLA HLA typing to support biotherapeutic immunogenicity risk assessment, vaccine development, and T cell research.

Product overview

ProImmune offers an integrated platform of immunological reagents and contract research services for T cell research, spanning MHC multimers (pentamers, tetramers, monomers), novel Ankyron binding reagents, custom peptide synthesis, and comprehensive assay services. The product portfolio centers on Pro5 MHC Class I Pentamers and ProT2/ProM2 MHC Class II reagents for detecting antigen-specific T cells, complemented by the innovative Ankyron target binding platform (engineered ankyrin-repeat proteins for any target). The services division includes ProPresent antigen presentation assays, ProMap/ProScern T cell proliferation assays, REVEAL epitope discovery, ProStorm cytokine release assays, and full immunogenicity assessment services for biotherapeutic development. The thinkpeptides custom synthesis brand provides peptides for epitope mapping and immune monitoring. Research applications span infectious diseases, oncology, autoimmunity, allergy, transplant immunology, and vaccine development.

Differentiator

Problem solved

Functional benefit

Brands

• Ankyrons®: Next-generation target binding reagents based on engineered ankyrin-repeat scaffold for detection and binding applications
• Pro5® MHC Class I Pentamers
• ProVE®
• ProT2® MHC Class II Tetramers
• ProM1™ MHC Class I Monomers
• ProM2® MHC Class II Monomers
• thinkpeptides®
• ProMix™ Peptide Pools
• REVEAL®
• ProPresent®
• ProMap®
• ProScern®
• ProStorm®
• ProSpot®
• typeHLA
• CD1d Tetramers
• MR1 Tetramers

Products and services

• Ankyrons® Next-generation target binding reagents (~15 kDa) based on engineered ankyrin-repeat scaffold proteins, generated through fully in vitro high-throughput selection from a trillion-clone ribosome display library without animal immunization; available for 60+ pathogens and rapidly developable for emerging disease targets. Used by immunology and infectious disease researchers as cost-effective, reproducible alternatives to custom antibodies.
• Pro5® MHC Class I Pentamers

Quantifiable outcome

• Ankyrons available for 60+ pathogens and disease vectors
• +2 more outcomes

Named customers17 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Three partnerships are on record, tiered core.

• University of Texas Medical Branch (UTMB) Galveston National LaboratorycoreStrategic or Co-development Partner · 14 April 2026Collaboration to develop innovative tools for studying high-consequence emerging and endemic infectious diseases. ProImmune's Ankyrons will be evaluated as molecular tools to enable precise detection, localization, and functional interrogation of viral proteins in high-containment research environments (BSL-4). Initial focus on Bundibugyo virus, Zaire ebolavirus, Sudan ebolavirus, Reston ebolavirus, Human Enterovirus 71, and Mpox virus.
• Roslin Institute (University of Edinburgh)coreStrategic or Co-development Partner · 18 March 2026Collaboration to develop and validate species-specific Ankyron binders for veterinary immunology research across porcine, bovine, avian, and salmonid species. Validated binder data will be made available through the Immunological Toolbox website, a BBSRC-funded initiative supporting the veterinary immunology research community.
• The Pirbright InstitutecoreStrategic or Co-development Partner · 1 October 2024Strategic partnership to develop target-binding Ankyron reagents for animal health research applications. ProImmune has generated and provided new Ankyrons to Pirbright for validation, including targets for bovine, porcine, avian, and mosquito proteins, as well as Foot and Mouth Disease and African Swine Fever - areas underserved by traditional antibody technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• MBL International: Japanese life science reagent company and the historical leader in MHC tetramers and multimer-based T cell detection. Directly competes with ProImmune's Pro5 Pentamers, ProT2 Tetramers, and CD1d/MR1 tetramers for the same immunology research customer base.
• Immudex: Denmark-based developer of MHC Dextramers and immune monitoring reagents used for antigen-specific T cell detection in research and clinical settings. Closely comparable in product format (multimers), application (flow cytometry), and target customer (immunology labs and cell therapy developers).
• JPT Peptide Technologies (Bio-Techne): Custom peptide synthesis and PepSpot/Peptide Microarray specialist serving immunology, vaccine, and immunogenicity customers. Directly comparable to ProImmune's thinkpeptides and PEPscreen custom peptide business and adjacent to its REVEAL epitope discovery service.
• GenScript: Global life science services and reagent provider offering custom peptide synthesis, antibody production, gene synthesis, and immunology-related services. Competes with ProImmune on custom synthesis, antibody alternatives, and immunogenicity-related CRO work.

Broad incumbents

• BioLegend (Revvity): Large catalog immunology reagent vendor offering flow cytometry antibodies, multimers, and immunoassay kits across research and translational markets. Competes on catalog breadth and bundled reagent panels rather than MHC specialization.
• Abcam (Danaher): One of the largest research antibody and reagent catalogs globally, including antibodies relevant to immunology, flow cytometry, and T cell biology. Competes with ProImmune's antibody offering and adjacent reagent categories, but at far greater catalog scale.
• Cell Signaling Technology: Major US research antibody and immunoassay reagent company with a deep catalog across immunology, immuno-oncology, and cell signaling. Competes indirectly with ProImmune in T cell and immunology reagent purchasing decisions, particularly in academic accounts.
• Beckman Coulter Life Sciences: Flow cytometry instruments and reagents vendor serving immunology and cell therapy labs worldwide. Competes for reagent dollars attached to flow cytometry workflows in which ProImmune's pentamers and tetramers are used.
• Eurofins Scientific: Global CRO with deep immunogenicity, bioassay, and vaccine testing capabilities. Competes with ProImmune's contract research services (ProPresent, ProMap, ProStorm, REVEAL) for outsourced immunogenicity and immunology assay work, particularly from large pharma.

Emerging players

• Navigo Proteins: German biotech developing alternative scaffold binding proteins (e.g., affilin scaffolds) for research and therapeutic applications. The closest direct technology analog to ProImmune's Ankyron platform, though focused on different scaffolds and primarily therapeutic use cases.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/proimmune

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ProImmune